Merck's New Product Development and Launch Strategy for Januvia |
ICMR HOME | Case Studies Collection
Custom Search
Please note: |
||||||
It's All About Speed Contd...
Thus Januvia was the only player in the estimated US$4 billion market for DPP-4 inhibitors and well on its way to becoming a blockbuster drug15. Merck also extended its lead over Galvus by getting another brand Janumet (a combination of Sitagliptin and a commonly used generic drug16 Metforin) approved for the treatment of Type 2 diabetes.
Custom Search
13] Pharmaceutical Executive is a magazine that
provides news and features from the world of pharmaceutical business. |
Case Studies Links:-
Case Studies,
Short Case Studies,
Simplified Case Studies.
Other Case Studies:-
Multimedia Case Studies,
Cases in Other Languages.
Business Reports Link:-
Business Reports.
Books:-
Text Books,
Work Books,
Case Study Volumes.